Cardiology

Original Research

Interleukin-6 Correlates with Endothelial Dysfunction in Young Post-Myocardial Infarction Patients

Eržen B. · Šabovič M. · Šebeštjen M. · Keber I. · Poredoš P.

Author affiliations

Department of Vascular Diseases, University Medical Centre, Ljubljana, Slovenia

Keywords: Interleukin-6Inflammation markersEndothelial dysfunctionMyocardial infarction

Related Articles for ""
Cardiology 2007;107:111–116
https://doi.org/10.1159/000094588

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Research

Received: December 21, 2005
Accepted: May 15, 2006
Published online: July 18, 2006
Issue release date: February 2007

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 4

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD

Abstract

Background: The estimation of coronary risk based on consideration of classical risk factors is insufficient in young patients with myocardial infarction who have low expressions of classical risk factors. Endothelial dysfunction (ED) and markers of vascular inflammation may be more appropriate for risk estimation. The relations among ED and inflammation markers in such patients have not yet been explored. Patients and Methods: Twenty-one patients (on average 44 years old) in the stable phase after myocardial infarction, with low expressions of risk factors, were included in the study. The control group consisted of 25 healthy age-matched males. ED was estimated by ultrasound measurement of the endothelium-dependent dilatation of the brachial artery. The following inflammation markers were measured: hsCRP, interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), ICAM-1, VCAM-1, selectin-P and selectin-E. Results: Patients had a significantly reduced level of endothelium-dependent vasodilatation (5.6 ± 3.5 vs. 8.8 ± 6.5%, p < 0.05), and an increased level of IL-6 (3.2 [1.5–8.4] vs. 1.4 [0.9–2.3] ng/ml; p < 0.01). All other inflammation markers were comparable to controls. We found a significant negative correlation between ED and the levels of IL-6 (r = –0.54, p = 0.012). Conclusion: It appears that IL-6 is the most valuable circulating marker of ED, and consequently a useful marker of coronary risk.

© 2007 S. Karger AG, Basel



Related Articles:

References

  1. Anderson TJ: Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 2003;8:71–86.
    External Resources
  2. Bonetti PO, Lerman LO, Lerman A: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168–175.
    External Resources
  3. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA: Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653–658.
    External Resources
  4. Aukrust P, Yndestad A, Waehre T, Gullestad L, Halvorsen B, Damas JK: Inflammation in coronary artery disease: potential role for immunomodulatory therapy. Expert Rev Cardiovasc Ther 2005;3:1111–1124.
    External Resources
  5. Koenig W, Rosenson RS: Acute-phase reactants and coronary heart disease. Semin Vasc Med 2002;2:417–428.
    External Resources
  6. Piro M, Giubilato G, Pinnelli M, Giordano Sciacca P, Biasucci LM: Endothelium and inflammation. Panminerva Med 2005;47:75–80.
    External Resources
  7. Yip HK, Wu CJ, Hang CL, Chang HW, Yang CH, Hsieh YK, Fang CY, Fu M, Yeh KH, Chen MC: Levels and values of inflammatory markers in patients with angina pectoris. Int Heart J 2005;46:571–581.
    External Resources
  8. Yamashita H, Shimada K, Seki E, Mokuno H, Daida H: Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 2003;91:133–136.
    External Resources
  9. Blum A, Schneider DJ, Sobel BE, Dauerman HL: Endothelial dysfunction and inflammation after percutaneous coronary intervention. Am J Cardiol 2004;94:1420–1423.
    External Resources
  10. Assmann G, Cullen P, Schulte H: Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Mal’nster (PROCAM) study. Circulation 2002;105:310–315.
    External Resources
  11. Kinlay S, Ganz P: Relation between endothelial dysfunction and the acute coronary syndrome: implications for therapy. Am J Cardiol 2000;86:10J–13J.
    External Resources
  12. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE: Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995;74:247–253.
    External Resources
  13. Ballantyne CM, Nambi V: Markers of inflammation and their clinical significance. Atheroscler Suppl 2005;6:21–29.
    External Resources
  14. Chlopicki S, Gryglewski RJ: Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium. Pharmacol Rep 2005;57(suppl):86–96.
  15. Wilson AM, Ryan MC, Boyle AJ: The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 2006;26;106:291–297.
    External Resources
  16. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000–1006.
    External Resources
  17. Wang P, Ba ZF, Chaudry IE: Administration of tumor necrosis factor alfa in vivo depresses endothelium-dependent relaxation. Am J Physiol 1994;266:H2535-H2541.
  18. Yoshizumi M, Perreila MA, Burnett JC, Lee ME: Tumor necrosis factor downregulates an endothelial nitric oxide synthase m RNA by shortening is half life. Circ Res 1993;73:205–209.
    External Resources
  19. Bhagt K, Vallance P: Inflammatory cytokines impair endothelium-dependent dilation in human veins in vivo. Circulation 1997;96:3042–3047.
    External Resources
  20. Furumoto T, Fujii S, Saito N, Mikami T, Kitabatke A: Relationship between brachial artery flow mediated dilation and carotid artery intima-media thickness in patients with suspected coronary artery disease. Jpn Heart J 2002;42:117–125.
    External Resources
  21. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction. Circulation 2000;18:1767–1772.

Article / Publication Details

First-Page Preview
Abstract of Original Research

Received: December 21, 2005
Accepted: May 15, 2006
Published online: July 18, 2006
Issue release date: February 2007

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 4

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2007, Vol.107, No. 2

February 2007

Article

Recommend This
Additional Information

Information about previous presentations: The manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language.

Conflicts of interest: none.

Support: The Slovenian Ministry of Science and Technology supported the study through grant No. 3311-01-831/463.
TOP